--- title: "Structure Therapeutics (GPCR) news: offering" url: "https://aibio.space/companies/structure-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GPCR offering news: Structure Therapeutics raises its at-the-market limit to $400,000,000. Structure Therapeutics Inc. (NASDAQ: GPCR), United States." --- GPCR Structure Therapeutics Inc. NASDAQ · United States # Structure Therapeutics (GPCR) news GPCR offering news Financings · 2026-05-07 ## [Structure Therapeutics raises its at-the-market limit to $400,000,000](https://aibio.space/news/structure-therapeutics-raises-market-limit-400-000-000/) Leerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement. ## Latest Structure Therapeutics news We have not published a story on Structure Therapeutics yet. When there is news, it will appear here. ## Structure Therapeutics at a glance - **Ticker**: GPCR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.34 billion ### Related companies - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Scorpius Holdings](https://aibio.space/companies/scorpius/) OTC: SCPX - [Cytokinetics](https://aibio.space/companies/cytokinetics/) NASDAQ: CYTK - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) NASDAQ: LTRN - [Harbor Diversified](https://aibio.space/companies/harbor-diversified/) OTC: HRBR - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) NASDAQ: ADIL ### Also on NASDAQ - [Bluejay Diagnostics](https://aibio.space/companies/bluejay-diagnostics/) BJDX - [TELA Bio](https://aibio.space/companies/tela-bio/) TELA - [Lexaria Bioscience](https://aibio.space/companies/lexaria-bioscience/) LEXX - [NervGen Pharma](https://aibio.space/companies/nervgen-pharma/) NGEN - [Curis](https://aibio.space/companies/curis/) CRIS - [Context Therapeutics](https://aibio.space/companies/context-therapeutics/) CNTX ## What Structure Therapeutics does Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for a wide range of chronic diseases with unmet medical need. Its platform combines structure-based drug discovery with computational chemistry to find small molecules against G-protein coupled receptors (GPCRs). Its most advanced candidate, aleniglipron (GSBR-1290), is an oral selective GLP-1 receptor agonist in five ongoing clinical studies for obesity, overweight and related conditions. The company also has two oral small molecule amylin receptor agonists: ACCG-2671, in Phase 1 clinical development, and ACCG-3535, selected as its second amylin development candidate. Its obesity pipeline includes preclinical discovery stage small molecules targeting glucose-dependent insulinotropic polypeptide and glucagon receptors, which the company says could be developed as monotherapies or in fixed dose combinations with its GLP-1 or amylin candidates. The text names type 2 diabetes, heart failure, sleep apnea, chronic kidney disease, MASH and osteoarthritis among the conditions these combinations could address. | Product or program | What it is | Stage | |---|---|---| | aleniglipron | Oral selective GLP-1 receptor agonist for obesity and related conditions | five ongoing clinical studies | | ACCG-2671 | Oral small molecule amylin receptor agonist | Phase 1 | | ACCG-3535 | Second oral amylin receptor agonist development candidate | development candidate | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/gpcr-20251231x10k.htm). ## Structure Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$225.3 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | [$108.8 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | | Net income (loss) | [-$141.2 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | [-$122.5 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | | Cash from operations | [-$222.2 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | [-$116.6 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | | Cash and equivalents | [$799.6 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/) | [$169.5 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | | Short-term investments | [$646.6 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/) | [$714.0 million](https://www.sec.gov/Archives/edgar/data/1888886/000110465926020562/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $272.6 million, plus short-term investments of $1.07 billion, $1.34 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Structure Therapeutics Has Structure Therapeutics raised money recently? Our latest story on this, dated May 7, 2026: "Structure Therapeutics raises its at-the-market limit to $400,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/structure-therapeutics-raises-market-limit-400-000-000/). What is the ticker symbol of Structure Therapeutics? Structure Therapeutics Inc. trades under the ticker GPCR on NASDAQ. Where is Structure Therapeutics listed? Structure Therapeutics Inc. is listed on NASDAQ. What is the SEC CIK of Structure Therapeutics? The SEC Central Index Key (CIK) for Structure Therapeutics Inc. is 1888886. Its filings are on SEC EDGAR. How many shares does Structure Therapeutics have outstanding? 213,929,572 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Structure Therapeutics listed under? Our directory records Structure Therapeutics Inc. under United States. What does Structure Therapeutics do? Our directory classifies Structure Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Structure Therapeutics? The ISIN recorded for Structure Therapeutics Inc. is US86366E1064. Does aibio.space cover Structure Therapeutics? aibio.space lists Structure Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Structure Therapeutics incorporated? SEC records list its state or country of incorporation as E9. What does Structure Therapeutics develop? Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for a wide range of chronic diseases with unmet medical need. Its platform combines structure-based drug discovery with computational chemistry to find small molecules against G-protein coupled receptors (GPCRs). What is aleniglipron from Structure Therapeutics? aleniglipron: Oral selective GLP-1 receptor agonist for obesity and related conditions Stage: five ongoing clinical studies. What is ACCG-2671 from Structure Therapeutics? ACCG-2671: Oral small molecule amylin receptor agonist Stage: Phase 1. Is Structure Therapeutics profitable? Structure Therapeutics Inc. reported a net loss of $141.2 million for the fiscal year ended Dec 31, 2025, and used $222.2 million of cash in operations, per its annual report to the SEC. How much does Structure Therapeutics spend on research and development? $225.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Structure Therapeutics Members talk about Structure Therapeutics (GPCR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Structure Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057160/tm2613720-1_424b5.htm) 2. 2025-12-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1888886/000110465925119370/tm2532078-3_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GPCR on TradingView](https://www.tradingview.com/symbols/NASDAQ-GPCR/). ## SEC filings and registration - **SEC name**: Structure Therapeutics Inc. - **CIK**: 1888886 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GPCR (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: (650) 457-1978 - **Shares outstanding**: 213,929,572 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: ShouTi Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm) filed 2026-09-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/gpcr-20260630x10q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926075720/tm2618249d1_8k.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057230/gpcr-20260331x10q.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_8k.htm) filed 2026-05-07 - [424B5](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057160/tm2613720-1_424b5.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1888886/000110465926047740/tm261564-1_def14a.htm) filed 2026-04-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001888886), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Structure Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GPCR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Structure Therapeutics Inc. - **Ticker**: GPCR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US86366E1064 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GPCR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/structure-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Structure Therapeutics (GPCR) news: offering", 2026-10-31, https://aibio.space/companies/structure-therapeutics/